Treatment efficacy of short-term PEG-IFN alpha for chronic hepatitis C patients with genotype 2 and low viral road

Treatment efficacy of short-term PEG-IFN alpha for chronic hepatitis C patients with genotype 2 and low viral road - GLSG, 2008, Pegasys

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001170

Enrollment

220

Registered

2014-05-01

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

a group of short-term PEG-IFN alpha therapy a group of ordinary-term PEG-IFN alpha therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C genotype 2 positive test of HCV-RNA and less than 5 LogIU/ml of HCV-RNA viral load abnormal transaminase negative test of HBsAg

Exclusion criteria

Exclusion criteria: liver dysfunction with other causes Allergy to Interferon (IFN) during pregnancy Severe comlication-especially, poor hematopoiesis, renal, cardiac or respiratory function

Design outcomes

Primary

Measure	Time frame
HCV-RNA	—

Secondary

Measure	Time frame
transaminase	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026